In vivo the presence of low adrenergic tone -for example, during supine rest -will allow partial 12 agonist activity of salbutamol to be expressed.7 In contrast, when adrenergic tone is raised -for example, during exercise -it would be expected that salbutamol should behave as a 12 antagonist relative to the activity of adrenaline. It should therefore be possible to characterise the partial 12 agonist/antagonist profile of salbutamol by comparing effects at rest and in response to exercise.
mmoUl. Whilst propranolol blunted exercise heart rate in keeping with P, blockade, salbutamol had no effect. Exercise produced an increase in lymphocyte P2 receptor binding density (Bmax) which was not affected by salbutamol. Plasma levels of adrenaline and noradrenaline at peak exercise were also unaltered by salbutamol in comparison with placebo. Conclusions -In a state of low adrenergic tone at rest salbutamol produces effects consistentwith P2 agonism. In Serum potassium levels were measured by flame photometry (IL943 analyser, Instrumentation Lab Ltd, Warrington, UK) with each sample analysed in duplicate. The normal reference range for our laboratory is 3 5-5 5 mmol/l, and the coefficients of variability for analytical imprecision within and between assays were 0-38% and 0-44%, respectively. Plasma levels of noradrenaline and adrenaline were assayed by the double isotope radioenzymatic method of Brown and Jenner. " The intra-assay coefficient of variation for this method in our laboratory is 8-0% and interassay coefficient of variation is 11 1%.
To determine Bmax and binding affinity (expressed as the dissociation constant for the radiolabelled antagonist -that is, Kd) 40 ml of whole blood was collected into tubes containing ethylene diaminetetraacetic acid. The methodology has previously been described and is given in brief here.'2 The blood was diluted to 50 ml with phosphate buffered saline (PBS) and two equal aliquots were centrifuged with 15 ml Lymphoprep (Nycomed Pharma AS, Oslo, Norway) and the lymphocyte layer removed. Following two further washes with PBS and centrifugation the lymphocyte pellet was resuspended in 5 ml PBS prior to lymphocyte counting. '251-iodocyano-pindolol (ICYP) (Nen-du Pont (UK) Ltd, Stevenage, UK) was used to determine Bmax and Kd. Eight concentrations ofICYP between 5 pM and 160 pM were used with CGP 1 2177 (Ciba-Geigy, Basle, Switzerland) being added to half the tubes to prevent ICYP binding to receptor sites, thus allowing non-specific binding to be evaluated. Specific receptor binding was calculated from total minus non-specific binding. The intraassay coefficient of variation for analytical imprecision was 10-29% for Bmax and 5-85% for Kd.
STATISTICAL ANALYSIS
Finger tremor data were transformed using logarithm to base 10 to achieve conformation with a normal distribution prior to analysis. Data were analysed using a Statgraphics statistical software package (STSC Software Publishing Group, Rockville, USA). Comparisons were made by multifactorial analysis ofvariance (MANOVA) using subjects, treatments, and periods as within factors for analysis. Where the overall MANOVA was significant Duncan's multiple range testing was then applied to establish where differences between treatments were significant, and in these cases the 95% confidence interval for the differences between the means was also calculated. A probability value of p<0Q05 (two tailed) was considered as being of significance for all tests. Values are given in the text either as means (SE) for each treatment, or as mean differences and 95% confidence intervals (CI) for differences between treatments.
Results

SUPINE REST (AFTER DRUG) (fig lA-C)
Salbutamol produced a dose-related stimulation of 12 receptors as evidenced by significant increases in resting heart rate and finger tremor, and a fall in serum potassium level. These effects were significantly different (p<005) from placebo at 4 mg and 8 mg doses; resting heart rate: (as mean difference) S4 v PL 18 (4 to 31) beats/min, S8 v PL 21 (7 to 34) beats/min, finger tremor: S4 v PL 0-68 (0-12 to 1-24) log units, S8 v PL 0 97 (0 39 to 1.54) log units, and serum potassium: S4 v PL -0-45 (-0-86 to -0-03) mmol/l, S8 v PL -0-59 (-1 -00 to -0 17) mmol/l.
EXERCISE RESPONSES (fig 2)
Propranolol significantly (p<0 05) attenuated the PI mediated heart rate delta response to exercise with placebo, indicating P1 adrenoceptor antagonism, whilst salbutamol had no effect (fig 2A) On maximal exercise during the step test, there is a much greater rise in noradrenaline levels than in levels of adrenaline. Vagal tone is also attenuated during exercise, although it has been shown with atropinisation that the predominant chronotropic effect is 13 adrenoceptor mediated.'0 The P1 adrenoceptor activity of noradrenaline is mainly responsible for the exercise-induced increase in heart rate, as evidenced by the lack of effect of selective P2 blockade with ICI 118 551.1516 The attenuation of exercise-induced heart rate by propranolol in our study was consistent with its known degree of PI blockade. In this respect the lack of effect of salbutamol on exercise-induced tachycardia is therefore indicative that the partial antagonism of salbutamol is 02 selective.
An increase in P2 receptor density occurred in response to exercise and this was unaffected by prior treatment with salbutamol. Thus, effects of salbutamol on P2 receptor density cannot therefore be invoked to explain the effects of salbutamol on exercise-induced hyperkalaemia as upregulation rather than downregulation was observed. The apparent rise in Kd with 4 mg salbutamol can be explained solely on the basis of a lower baseline value since the values after exercise did not significantly differ between doses of salbutamol. The observed rise in Bmax with exercise is consistent with previously published data.'7-20 The precise mechanism for this response remains unclear, although there is evidence to suggest that it may be the result of catecholamine-induced changes in the composition of the circulating pool of lymphocytes, such that cells relatively rich in P2 receptors are released into the circulation to a greater extent than those with a lower receptor density. [21] [22] [23] [24] In the present study the systemic responses of normal volunteers were studied. It is, however, conceivable that, even in the airway, in the presence of raised levels of endogenous adrenergic tone, salbutamol may act as an antagonist at bronchial 132 adrenoceptors. In this regard there is in vitro evidence in guinea pig airway that salbutamol, despite being a full agonist when given alone, was shown to antagonise competitively the relaxant effect of isoprenaline in the presence of carbachol-induced bronchoconstriction.' This illustrates the important principle that it is only possible properly to assess agonist/antagonist activity in the presence of a full agonist, whether it be isoprenaline in vitro or adrenaline in vivo. Further studies in asthmatic subjects may therefore be warranted to investigate this effect in vivo, with its possible relevance in the setting ofacute asthma if adrenergic tone is increased, in a patient who may also be taking high doses of 12 agonists.
Furthermore, it would be interesting to know whether there are differences in activity between partial 12 agonists such as salbutamol and salmeterol and full agonists such as fenoterol and formoterol, particularly when adrenergic tone is increased. 
